> YMI AeroLef – I don't remember discussing this ad nauseam, and I disagree.<
Since you’re a paid member of iHub, you can use iHub’s Search tool to pull up the threads on this topic. :-) But I’ll give you my recollection anyhow.
>I don't know how the obvious difference between buccal and inhaled adminstration in timecourse to effect can be construed as marketing spin. We're talking about 15 minutes versus seconds.<
AeroLef does not produce discernable symptom relief in seconds—no drug for breakthrough cancer pain can do that. What AeroLef does do is get into the bloodstream within seconds, which is quite another matter.
The “spin” on YMI’s part was in their presenting slides on AeroLef’s pharmacokinetics while simultaneously touting the drug’s fast onset of symptom relief during an investor conference. I don’t know whether this was intentionally misleading or just sloppy, but the result was that some investors improperly inferred that AeroLef could relieve symptoms within seconds.
Market Data 
Markets 
AI
